← All Nymox Pharmaceutical CORP filings

Nymox Pharmaceutical CORP 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

OQB
NYMXF
Nymox Pharmaceutical CORP
20-F: Nymox Pharmaceutical Faces Significant Going Concern Doubts Amidst Continued Losses and Regulatory Setbacks for Key Drug Candidate
Nymox Pharmaceutical Corporation reported a net loss of $4.5 million for 2024, accumulating a deficit of $212.5 million, and disclosed substantial doubt about its ability to continue as a going concern due to insufficient cash and lack of product sales.
OQB
NYMXF
Nymox Pharmaceutical CORP
20-F: Nymox Pharmaceutical Corporation Reports Losses in 2023 Amid Ongoing Development Efforts
Nymox Pharmaceutical Corporation's 2023 20-F filing reveals continued operating losses and a focus on advancing its drug candidate NX-1207 through regulatory approval processes.